NOT FDA-APPROVED FOR ANY USE
What is CJC-1295 / Ipamorelin?
This combination pairs CJC-1295, a growth-hormone releasing hormone (GHRH) analog, with ipamorelin, a selective growth-hormone secretagogue. Researchers have studied this pairing for potentially additive or synergistic effects on growth hormone release compared to either compound alone.
Areas of Research Interest
- Synergistic growth hormone release pathway studies
- Combination-therapy research design
- Body composition and recovery research
- Sleep quality studies
Regulatory Status
Neither CJC-1295 nor ipamorelin, individually or combined, are FDA-approved for any human or veterinary use. This combination has not completed human clinical trials and is classified as a research chemical intended solely for laboratory research.
Educational information only. This content is not intended to diagnose, treat, cure, or prevent any disease, and does not provide guidance on personal use, dosing, or administration. Consult qualified professionals and current regulatory sources for guidance specific to your situation.